Results for: Prostate

8 Trials Avaliable

  • GU 151

    A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY OF TAS3681 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER

  • GU 156

    An Open-label, Multi-drug, Multi-center Phase II Combination Study ofnAZD4635 in Patients with Prostate Cancer

  • GU 160

    A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy

  • GU 168

    A phase 1, open-label, dose escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer who have progressed on at least two prior systemic therapies

  • GU 170

    A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYnOF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATICnCASTRATION-RESISTANT PROSTATE CANCER

  • GU 178

    A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28)WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

  • GU 182

    A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • RM 557

    A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)